Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature
This case series supports the use of tocilizumab as a therapeutic option for rapid resolution of haemolysis. It is generally widely available and should be considered a suitable and cost-effective alternative to currently available options.
Authors
- S. Bennett
- Sonia Wolf (ORCID: https://orcid.org/0000-0003-2110-8232)
- Paul Telfer (ORCID: https://orcid.org/0000-0003-4960-5134)
- Funmi Oyesanya
- Bhagteshwar Singh (ORCID: https://orcid.org/0000-0002-9039-3674)
- Burak Kaya (ORCID: https://orcid.org/0000-0001-8516-3658)
- F. Barroso
- Abbas Zaidi (ORCID: https://orcid.org/0000-0003-2256-3448)
- Paul Greaves (ORCID: https://orcid.org/0000-0002-3318-7233)
Institutions
- Barking, Havering And Redbridge University Hospitals NHS Trust (GB)
- NHS Blood and Transplant (GB)
- Queen Mary University of London (GB)
- Barts Health NHS Trust (GB)
Publication Details
- Journal
- Transfusion Medicine
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1111/tme.70026
- Primary Topic
- Blood groups and transfusion
- Type
- article
- Field-Weighted Citation Impact
- 0.00